Banner
Biotechnology

Amgen, Inc. (Nasdaq: AMGN) – FYE 12/2020 – FAIRLY VALUED – The stock is currently trading at levels above my most recent $213 initiate target, but below my most recent $380 reduce target. Please See Linked PDF Worksheet.
Revised on 09/24/2021

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) – FYE 12/2020 – UNDER VALUED – The stock is currently trading at levels below my most recent $204 initiate target. Please See Linked PDF Worksheet.
Revised on 02/28/2021

Emergent BioSolutions, Inc. (NYSE: EBS) – FYE 12/2019 – OVER VALUED – The stock is currently trading at levels above my most recent $61 terminate target. Please See Linked PDF Worksheet.
Revised on 01/27/2021

Gilead Sciences, Inc. (Nasdaq: GILD) – FYE 12/2020 – FAIRLY VALUEDOVER VALUED – The stock is currently trading at levels above my most recent $61 terminate target. Please See Linked PDF Worksheet.
Revised on 10/27/2021

Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) – FYE 12/2020 – FAIRLY VALUED – The stock is currently trading at levels above my most recent $436 initiate target, but below my most recent $778 reduce target. Please See Linked PDF Worksheet.
Revised on 10/29/2021

Repligen Corporation (Nasdaq: RGEN) – FYE 12/2020 – OVER VALUED – The stock is currently trading at levels above my most recent $58 terminate target. Please See Linked PDF Worksheet.
Revised on 10/30/2021

Please note that worksheets are updated basis the most current SEC 10-K ANNUAL filing.